

Data + Perspectives
**Exploring the Role of Novel Agents
and Emerging Strategies in the Management
of Acute Myeloid Leukemia**

Friday, December 6, 2019

7:30 AM – 9:30 AM

Orlando, Florida

Moderator

Neil Love, MD

Faculty

Mark Levis, MD, PhD

Daniel A Pollyea, MD, MS

Richard M Stone, MD

Andrew H Wei, MBBS, PhD

Disclosures for Moderator Neil Love, MD

Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

Agenda

Module 1 – Dr Pollyea: *Evolving Paradigms in Up-Front Treatment for Older Patients or Those Ineligible for Intensive Chemotherapy*

Module 2 – Dr Stone: *Assessment, Incidence and Clinical Significance of FLT3 Mutations in AML*

Module 3 – Dr Levis: *Long-Term Treatment for Patients with AML with IDH Mutations*

Module 4 – Prof Wei: *Other Novel Agents and Promising Strategies Under Evaluation for Patients with AML*

The patients I saw today...

82	M	Chronic myeloid leukemia - Newly diagnosed, Sokal intermediate risk, I recommended dasatinib
42	F	Breast Cancer - Stage III TNBC s/p adjuvant DD AC-T
89	M	Acute Myeloid Leukemia - Venetoclax/azacitidine
38	F	Colorectal Cancer - Metastatic colon cancer on FOLFOX/bevacizumab
76	M	Hepatocellular carcinoma – Nivolumab
71	F	Diffuse Large B Cell Lymphoma - Completed R-CHOP
84	M	Multiple myeloma - Bortezomib/Dex
59	M	Multiple myeloma or other plasma cell dyscrasias – Maintenance Carfilzomib/Dex
62	M	Multiple myeloma - Relapsed/Refractory- Carfilzomib/Cyclophosphamide/Dex

72	F	Breast Cancer – Anastrozole
54	F	Breast Cancer – Tamoxifen
35	M	Benign Hematology - Enoxaparin for DVT
32	F	Benign Hematology - DSVT on warfarin
40	F	Benign Hematology - Iron def anemia on oral iron
42	F	T-Cell Lymphoma - T-Cell LGL on weekly Methotrexate
68	M	Diffuse Large B Cell Lymphoma - Primary CNS lymphoma s/p HD- Methotrexate/Rituximab
57	F	Melanoma - Ipi/Nivo
62	M	Renal Cell Carcinoma - Ipi/Nivo
62	M	Lung Cancer - Consolidative Durvalumab after chemoRT
92	M	Prostate cancer - Enzalutamide/Leuprolide/Denosumab

Exploring Current Management Paradigms for Patients with Acute Myeloid Leukemia Not Eligible for Intensive Therapy

Friday, October 25, 2019, 1:15 PM – 3:45 PM
Orlando, Florida

Faculty

Courtney D DiNardo, MD, MSCE

Keith W Pratz, MD

Richard M Stone, MD

Moderator

Neil Love, MD

Research
To Practice®



Survey Participants

Amy DeZern, MD, MHS

Courtney D DiNardo, MD, MSCE

James Dugan, MD

Harry P Erba, MD, PhD

Amir Fathi, MD

Steven D Gore, MD

Jonathan A Gutman, MD

Catherine Lai, MD

Thomas LeBlanc, MD

Mark Levis, MD, PhD

Gabriel Mannis, MD

Rebecca Olin, MD, MSCE

Alexander Perl, MD, MS

Daniel A Pollyea, MD, MS

Keith W Pratz, MD

Farhad Ravandi, MD

Gary J Schiller, MD

Eytan M Stein, MD

Wendy Stock, MD

Richard M Stone, MD

Kendra Sweet, MD, MS

Geoffrey L Uy, MD

Roland Walter, MD, PhD, MS

Eunice Wang, MD

Andrew H Wei, MBBS, PhD

Joshua F Zeidner, MD

N = 26 investigators

What initial treatment would you recommend for a 65-year-old man with AML with a PS of 1 and pancytopenia, 35% marrow myeloblasts, a complex karyotype and a TP53 mutation?

